Emergo Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Emergo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).
SEC Form D · Oct 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2020
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Emergo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Moise Khayrallah | Executive officer | Oct 2020 |
| Robin Hyde-DeRuyscher | Executive officer | Sep 2019 |
| John E. Bailey, Jr. | Director | Oct 2020 |
| Margaret E. Powell | Director | Oct 2020 |
| Moise Khayrallah | Director | Oct 2020 |
| Robert E. Helmedag | Director | Oct 2020 |